Dyne Therapeutics (NASDAQ:DYN) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a sell rating to a hold rating in a report published on Saturday morning.

Several other research analysts also recently issued reports on the stock. Stifel Nicolaus boosted their price objective on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. HC Wainwright lifted their target price on Dyne Therapeutics from $46.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Cowen restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Lifesci Capital raised Dyne Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Oppenheimer upgraded Dyne Therapeutics from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $11.00 to $40.00 in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.47.

Dyne Therapeutics Stock Up 7.0%

DYN opened at $19.85 on Friday. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $26.22. The company has a current ratio of 13.47, a quick ratio of 13.47 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of -5.42 and a beta of 1.30. The business has a 50 day moving average of $19.70 and a 200-day moving average of $14.53.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Wednesday, November 5th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.05. As a group, sell-side analysts anticipate that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Institutional Investors Weigh In On Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in DYN. Darwin Wealth Management LLC grew its stake in shares of Dyne Therapeutics by 0.5% in the 3rd quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock valued at $2,195,000 after purchasing an additional 861 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Dyne Therapeutics by 11.1% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after buying an additional 955 shares in the last quarter. Creative Planning grew its position in Dyne Therapeutics by 6.8% in the third quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after acquiring an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after acquiring an additional 1,109 shares in the last quarter. Finally, Caxton Associates LLP raised its stake in Dyne Therapeutics by 10.9% during the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after acquiring an additional 1,627 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.